newsfilter
← Latest News
GlobeNewswire·

Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting

  • Biodesix, Inc. will present new data from its tumor-informed & tumor-naïve molecular residual disease (MRD) programs at the Association for Molecular Pathology (AMP) 2026 Annual Meeting in Seattle, November 10-14, 2026.
  • The company will present three posters & host a Corporate Workshop featuring collaborators Bio-Rad Laboratories & Thermo Fisher Scientific.
  • Biodesix announced two complementary MRD programs in September 2026: a tumor-informed solution using Bio-Rad's Droplet Digital™ PCR & a tumor-naïve, methylation-based solution under development with Thermo Fisher Scientific on the Ion Torrent™ Genexus™ platform.
  • Both MRD programs are being validated in collaboration with Memorial Sloan Kettering Cancer Center & are designed to run on partner platforms already installed in laboratories globally.
  • The Corporate Workshop on November 11, 2026, will feature speakers discussing complementary approaches to detecting circulating tumor DNA, monitoring emerging resistance via the GeneStrat® ESR1 ddPCR™ Test, & the validation studies required for clinical use.
  • Poster I020 will detail a scalable, tissue-independent bioinformatics framework for designing personalized ddPCR-based MRD assays from existing sequencing data.
  • Poster ST011 will describe a whole-genome sequencing-informed workflow to deploy bespoke multiplexed ddPCR assays capable of tracking single nucleotide & structural variants.
  • Poster ST147 will present data on a tumor-naïve, methylation-based MRD solution using plasma from whole blood collected in stabilizer tubes.
  • Biodesix Development Services team members will be at booth 544 at the convention center to discuss translational research & diagnostic solutions.
Company
Biodesix, Inc.
Keywords
Nasdaq:BDSX, Biodesix, Inc.